{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T05:34:49Z","timestamp":1695706489852},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T00:00:00Z","timestamp":1690761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02825-9","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T14:02:14Z","timestamp":1690812134000},"page":"4079-4086","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of different conbercept injection regimens in the treatment of choroidal neovascularization in pathological myopia: a retrospective study"],"prefix":"10.1007","volume":"43","author":[{"given":"Bin","family":"Gong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxia","family":"Bo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,31]]},"reference":[{"issue":"5","key":"2825_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","volume":"159","author":"K Ohno-Matsui","year":"2015","unstructured":"Ohno-Matsui K, Kawasaki R, Jonas JB, Cheung CM, Saw SM, Verhoeven VJ, Klaver CC, Moriyama M, Shinohara K, Kawasaki Y, Yamazaki M, Meuer S, Ishibashi T, Yasuda M, Yamashita H, Sugano A, Wang JJ, Mitchell P, Wong TY (2015) International photographic classification and grading system for myopic maculopathy. Am J Ophthalmol 159(5):877\u201383.e7. https:\/\/doi.org\/10.1016\/j.ajo.2015.01.022","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"2825_CR2","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.ophtha.2015.03.018","volume":"122","author":"KM Williams","year":"2015","unstructured":"Williams KM, Bertelsen G, Cumberland P, Wolfram C, Verhoeven VJ, Anastasopoulos E, Buitendijk GH, Cougnard-Gr\u00e9goire A, Creuzot-Garcher C, Erke MG, Hogg R, H\u00f6hn R, Hysi P, Khawaja AP, Korobelnik JF, Ried J, Vingerling JR, Bron A, Dartigues JF, Fletcher A, Hofman A, Kuijpers RW, Luben RN, Oxele K, Topouzis F, von Hanno T, Mirshahi A, Foster PJ, van Duijn CM, Pfeiffer N, Delcourt C, Klaver CC, Rahi J, Hammond CJ (2015) Increasing prevalence of myopia in europe and the impact of education. Ophthalmology 122(7):1489\u20131497. https:\/\/doi.org\/10.1016\/j.ophtha.2015.03.018","journal-title":"Ophthalmology"},{"issue":"7","key":"2825_CR3","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/s0161-6420(03)00461-5","volume":"110","author":"T Yoshida","year":"2003","unstructured":"Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, Tokoro T, Mochizuki M (2003) Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology 110(7):1297\u20131305. https:\/\/doi.org\/10.1016\/s0161-6420(03)00461-5","journal-title":"Ophthalmology"},{"issue":"5","key":"2825_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1136\/bjo.87.5.570","volume":"87","author":"K Ohno-Matsui","year":"2003","unstructured":"Ohno-Matsui K, Yoshida T, Futagami S, Yasuzumi K, Shimada N, Kojima A, Tokoro T, Mochizuki M (2003) Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 87(5):570\u2013573. https:\/\/doi.org\/10.1136\/bjo.87.5.570","journal-title":"Br J Ophthalmol"},{"key":"2825_CR5","doi-asserted-by":"publisher","unstructured":"Zhu Y, Zhang T, Xu G, Peng L (2016) Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia. Cochrane Database Syst Rev 12(12):Cd011160. https:\/\/doi.org\/10.1002\/14651858.CD011160.pub2","DOI":"10.1002\/14651858.CD011160.pub2"},{"issue":"3","key":"2825_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","volume":"141","author":"JP Tong","year":"2006","unstructured":"Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS (2006) Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 141(3):456\u2013462. https:\/\/doi.org\/10.1016\/j.ajo.2005.10.012","journal-title":"Am J Ophthalmol"},{"key":"2825_CR7","doi-asserted-by":"publisher","unstructured":"Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92\u2013106. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.10.005","DOI":"10.1016\/j.preteyeres.2017.10.005"},{"issue":"6","key":"2825_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1097\/iae.0000000000001313","volume":"37","author":"K Kasahara","year":"2017","unstructured":"Kasahara K, Moriyama M, Morohoshi K, Yoshida T, Simada N, Nagaoka N, Yokoi T, Shinohara K, Kaneko Y, Suga M, Ohno-Matsui K (2017) Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia. Retina 37(6):1055\u20131064. https:\/\/doi.org\/10.1097\/iae.0000000000001313","journal-title":"Retina"},{"issue":"6","key":"2825_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/eye.2013.8","volume":"27","author":"A Tufail","year":"2013","unstructured":"Tufail A, Patel PJ, Sivaprasad S, Amoaku W, Browning AC, Cole M, Gale R, George S, Lotery AJ, Majid M, McKibbin M, Menon G, Yang Y, Andrews C, Brittain C, Osborne A (2013) Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study. Eye (Lond) 27(6):709\u2013715. https:\/\/doi.org\/10.1038\/eye.2013.8","journal-title":"Eye (Lond)"},{"issue":"11","key":"2825_CR10","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","volume":"124","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Arnold JJ, Holz FG, Park KH, Lai TYY, Larsen M, Mitchell P, Ohno-Matsui K, Chen SJ, Wolf S, Wong TY (2017) Myopic choroidal neovascularization: review, guidance, and consensus statement on management. Ophthalmology 124(11):1690\u20131711. https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.028","journal-title":"Ophthalmology"},{"issue":"7","key":"2825_CR11","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","volume":"33","author":"E Wang","year":"2013","unstructured":"Wang E, Chen Y (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33(7):1375\u20131392. https:\/\/doi.org\/10.1097\/IAE.0b013e31827d260a","journal-title":"Retina"},{"issue":"4","key":"2825_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000478030","volume":"238","author":"C Calvo-Gonz\u00e1lez","year":"2017","unstructured":"Calvo-Gonz\u00e1lez C, Reche-Frutos J, Fern\u00e1ndez-Vigo JI, S\u00e1enz-Franc\u00e9s F, Fern\u00e1ndez-P\u00e9rez C, Garc\u00eda-Feij\u00f3o J (2017) Long-term outcomes of two different initial dosing regimens of intravitreal Ranibizumab used to treat myopic choroidal neovascularization. Ophthalmologica 238(4):196\u2013204. https:\/\/doi.org\/10.1159\/000478030","journal-title":"Ophthalmologica"},{"issue":"8","key":"2825_CR13","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1111\/aos.12457","volume":"92","author":"YH Kung","year":"2014","unstructured":"Kung YH, Wu TT, Huang YH (2014) One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol 92(8):e615\u2013e620. https:\/\/doi.org\/10.1111\/aos.12457","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"2825_CR14","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY, Korobelnik JF, Vitti R, Li T, Stemper B, Asmus F, Zeitz O, Ishibashi T (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122(6):1220\u20131227. https:\/\/doi.org\/10.1016\/j.ophtha.2015.01.025","journal-title":"Ophthalmology"},{"issue":"1","key":"2825_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11095-008-9718-9","volume":"26","author":"M Zhang","year":"2009","unstructured":"Zhang M, Yu D, Yang C, Xia Q, Li W, Liu B, Li H (2009) The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 26(1):204\u2013210. https:\/\/doi.org\/10.1007\/s11095-008-9718-9","journal-title":"Pharm Res"},{"issue":"9","key":"2825_CR16","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, Luo D, Ke X (2014) Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121(9):1740\u20131747. https:\/\/doi.org\/10.1016\/j.ophtha.2014.03.026","journal-title":"Ophthalmology"},{"key":"2825_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-318690","author":"K Liu","year":"2021","unstructured":"Liu K, Wang H, He W, Ye J, Song Y, Wang Y, Liu X, Wu Z, Chen S, Fan K, Liu Y, Zhang F, Li Z, Liu L, Zhang J, Zhang X, Ye J, Liang X, Li X, Ke X, Wu Q, Li J, Tao S, Wang X, Rosenfeld P, Heier JS, Kaiser P, Xu X (2021) Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-318690","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"2825_CR18","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1111\/aos.13632","volume":"97","author":"M Yan","year":"2019","unstructured":"Yan M, Huang Z, Lian HY, Song YP, Chen X (2019) Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol 97(5):e813\u2013e814. https:\/\/doi.org\/10.1111\/aos.13632","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"2825_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12886-021-01877-8","volume":"21","author":"X Nie","year":"2021","unstructured":"Nie X, Wang Y, Yi H, Qiao Y (2021) Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China: intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol 21(1):116. https:\/\/doi.org\/10.1186\/s12886-021-01877-8","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"2825_CR20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/bjo.2008.138891","volume":"92","author":"PA Keane","year":"2008","unstructured":"Keane PA, Liakopoulos S, Chang KT, Heussen FM, Ongchin SC, Walsh AC, Sadda SR (2008) Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol 92(8):1081\u20131085. https:\/\/doi.org\/10.1136\/bjo.2008.138891","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"2825_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","volume":"128","author":"MH Maloney","year":"2021","unstructured":"Maloney MH, Payne SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ (2021) Risk of systemic adverse events after intravitreal bevacizumab, Ranibizumab, and Aflibercept in routine clinical practice. Ophthalmology 128(3):417\u2013424. https:\/\/doi.org\/10.1016\/j.ophtha.2020.07.062","journal-title":"Ophthalmology"},{"issue":"2","key":"2825_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","volume":"159","author":"HJ Cho","year":"2015","unstructured":"Cho HJ, Yoo SG, Kim HS, Kim JH, Kim CG, Lee TG, Kim JW (2015) Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation. Am J Ophthalmol 159(2):285\u201392.e1. https:\/\/doi.org\/10.1016\/j.ajo.2014.10.035","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2825_CR23","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.ajo.2015.02.020","volume":"159","author":"C Sch\u00fctze","year":"2015","unstructured":"Sch\u00fctze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U (2015) Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol 159(6):1100-1114.e1. https:\/\/doi.org\/10.1016\/j.ajo.2015.02.020","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2825_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3):682\u201392.e2. https:\/\/doi.org\/10.1016\/j.ophtha.2013.10.023","journal-title":"Ophthalmology"},{"key":"2825_CR25","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.2147\/dddt.S67536","volume":"9","author":"X Lu","year":"2015","unstructured":"Lu X, Sun X (2015) Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther 9:2311\u20132320. https:\/\/doi.org\/10.2147\/dddt.S67536","journal-title":"Drug Des Devel Ther"},{"key":"2825_CR26","doi-asserted-by":"publisher","first-page":"2674780","DOI":"10.1155\/2020\/2674780","volume":"2020","author":"TT Yao","year":"2020","unstructured":"Yao TT, Jin XL, Yang Y, Wang YX, Zhou YL, He FL, Wang ZY (2020) Intraocular pharmacokinetics and safety of subretinal injection compared with intravitreal application of conbercept in vitrectomized rabbit eyes. J Ophthalmol 2020:2674780. https:\/\/doi.org\/10.1155\/2020\/2674780","journal-title":"J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02825-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02825-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02825-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T11:10:10Z","timestamp":1695640210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02825-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,31]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["2825"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02825-9","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,31]]},"assertion":[{"value":"19 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The present study was reviewed and approved by the Institutional Review Board of Jinan 2nd People's Hospital (approval number: [2019] 018) and was conducted in compliance with the principles of the <i>Declaration of Helsinki<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}